Novo Nordisk, Wegovy

Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss
Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the weight loss achieved with Eli Lilly's rival drug Zepbound,
Novo Nordisk’s Wegovy Achieves Weight-Loss of 20.7% at Higher Dose, Study Says
Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, without experiencing an increase in side-effects.
Novo Trial Shows Bigger Dose of Wegovy Helps Shed Pounds
Novo Nordisk A/S said a bigger dose of the main ingredient in Wegovy, its top-selling weight-loss drug, helped patients shed more pounds in a trial than a standard dosage.
Novo Nordisk says its high-dose semaglutide trial shows 20.7% weight loss
Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight patients lower their weight by 20.7%.
Novo Nordisk's Ozempic & Wegovy in 2027 Medicare price talks
GLP-1 weight loss drugs, Ozempic and Wegovy, will be targeted in the next round of Medicare price negotiations in 2027, along with 13 other medications. Seana Smith and Brad Smith break down the details on Morning Brief.
Novo’s Wegovy Trails Lilly’s Rival in High-Dose Study
Raising the dose of Novo Nordisk A/S’s obesity drug Wegovy helped patients shed more pounds in a trial while still falling short of the weight loss seen with rival Eli Lilly & Co.’s Zepbound.
Tripling Wegovy dosage leads to more weight loss, Novo Nordisk trial shows
Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday. The Danish drugmaker announced results from a Phase 3B trial of semaglutide at a 7.2 milligram dosage,
High-dose Wegovy leads to substantial weight loss in trial, but falls short of Zepbound
A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with Zepbound.
US targets Novo Nordisk's Ozempic and Wegovy for Medicare price talks
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...
Novo Nordisk's stock down 4% as the Feds get ready for a second round of drug price negotiations
Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.
LVMH Reclaims Title of Europe’s Most Valuable Stock From Novo
It’s taken LVMH nearly a year-and-a-half to regain its spot as Europe’s biggest stock from Novo Nordisk A/S.
Novo’s Ozempic, Wegovy Targeted for Medicare Price Cuts (3)
The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...
Novo Nordisk says high-dose semaglutide trial shows 20.7% weight loss
Novo Nordisk said on Friday a late-stage trial with a high-dose version of the active ingredient semaglutide, used in its ...
Novo Nordisk Unusual Options Activity
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Novo Nordisk data boosts H.C. Wainwright confidence in Viking’s potential
After Novo Nordisk (NVO) reported results from its Phase 3b STEP UP trial, which showed that adults with obesity achieved a 20.7% weight loss ...